Overview Fundamentals API Earnings EOD API Sample Code Pricing

Cingulate Inc. Warrants (CINGW NASDAQ) stock market data APIs

$0.0099 0(0%) as of July 12, 2024
Price chart is built with Anychart

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc. Warrants Financial Data Overview

Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CINGW',
Type: 'Common Stock',
Name: 'Cingulate Inc. Warrants',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG013YMVH68',
CIK: '1862150',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-12-08',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Warrant',
IsDelisted: false,

Cingulate Inc. Warrants Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -21 211 522
  • Earnings Per Share -1.732
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Cingulate Inc. Warrants Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get Cingulate Inc. Warrants End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?